Tags

Type your tag names separated by a space and hit enter

Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study.
J Alzheimers Dis 2013; 36(1):1-6JA

Abstract

Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer's disease (AD). N - 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n - 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to receive 1.7 g DHA and 0.6 g EPA (n - 3/n - 3 group) or placebo (placebo/n - 3 group) during 6 months. After 6 months, all patients received n - 3 FA for another 6 months. TTR and FA were measured in plasma in all subjects, whereas TTR in cerebrospinal fluid (CSF) was measured in a subgroup. The study was completed by 89 patients in the n - 3/n - 3 group (75 y, 57% w) and 85 in the placebo/n - 3 group (75 y, 46% w). Baseline plasma-TTR was within normal range in both groups. After 6 months, plasma-TTR decreased in the placebo/n - 3 group (p < 0.001 within and p < 0.015 between the groups). No changes were observed in CSF TTR. From 6 to 12 months when both groups were supplemented, plasma-TTR increased significantly in both groups. Repeated measures ANOVA indicated an increase in TTR over time (p = 0.04) in those receiving n - 3 FA for 12 months. By linear regression analyses, n - 3 FA treatment was independently associated with increased plasma-TTR at 6 months (β = -0.172, p = 0.028). Thus, n - 3 FA treatment appeared to increase plasma-TTR in patients with AD. Since TTR may influence Aβ deposition in the brain, the results warrant further exploration.

Authors+Show Affiliations

Department of NVS, Section of Clinical Nutrition, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. gerd.faxen.irving@ki.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23563245

Citation

Faxén-Irving, Gerd, et al. "Effects On Transthyretin in Plasma and Cerebrospinal Fluid By DHA-rich N - 3 Fatty Acid Supplementation in Patients With Alzheimer's Disease: the OmegAD Study." Journal of Alzheimer's Disease : JAD, vol. 36, no. 1, 2013, pp. 1-6.
Faxén-Irving G, Freund-Levi Y, Eriksdotter-Jönhagen M, et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. J Alzheimers Dis. 2013;36(1):1-6.
Faxén-Irving, G., Freund-Levi, Y., Eriksdotter-Jönhagen, M., Basun, H., Hjorth, E., Palmblad, J., ... Wahlund, L. O. (2013). Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease : JAD, 36(1), pp. 1-6. doi:10.3233/JAD-121828.
Faxén-Irving G, et al. Effects On Transthyretin in Plasma and Cerebrospinal Fluid By DHA-rich N - 3 Fatty Acid Supplementation in Patients With Alzheimer's Disease: the OmegAD Study. J Alzheimers Dis. 2013;36(1):1-6. PubMed PMID: 23563245.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. AU - Faxén-Irving,Gerd, AU - Freund-Levi,Yvonne, AU - Eriksdotter-Jönhagen,Maria, AU - Basun,Hans, AU - Hjorth,Erik, AU - Palmblad,Jan, AU - Vedin,Inger, AU - Cederholm,Tommy, AU - Wahlund,Lars-Olof, PY - 2013/4/9/entrez PY - 2013/4/9/pubmed PY - 2013/12/16/medline SP - 1 EP - 6 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 36 IS - 1 N2 - Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer's disease (AD). N - 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n - 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to receive 1.7 g DHA and 0.6 g EPA (n - 3/n - 3 group) or placebo (placebo/n - 3 group) during 6 months. After 6 months, all patients received n - 3 FA for another 6 months. TTR and FA were measured in plasma in all subjects, whereas TTR in cerebrospinal fluid (CSF) was measured in a subgroup. The study was completed by 89 patients in the n - 3/n - 3 group (75 y, 57% w) and 85 in the placebo/n - 3 group (75 y, 46% w). Baseline plasma-TTR was within normal range in both groups. After 6 months, plasma-TTR decreased in the placebo/n - 3 group (p < 0.001 within and p < 0.015 between the groups). No changes were observed in CSF TTR. From 6 to 12 months when both groups were supplemented, plasma-TTR increased significantly in both groups. Repeated measures ANOVA indicated an increase in TTR over time (p = 0.04) in those receiving n - 3 FA for 12 months. By linear regression analyses, n - 3 FA treatment was independently associated with increased plasma-TTR at 6 months (β = -0.172, p = 0.028). Thus, n - 3 FA treatment appeared to increase plasma-TTR in patients with AD. Since TTR may influence Aβ deposition in the brain, the results warrant further exploration. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/23563245/Effects_on_transthyretin_in_plasma_and_cerebrospinal_fluid_by_DHA_rich_n___3_fatty_acid_supplementation_in_patients_with_Alzheimer's_disease:_the_OmegAD_study_ L2 - https://content.iospress.com/openurl?genre=article&amp;id=doi:10.3233/JAD-121828 DB - PRIME DP - Unbound Medicine ER -